#NICE #NICEFAD #NICEfinaldraftguidance #Alzheimerstreatments #NHS #donanemab #Kisunla #EliLilly #lecanemab #Leqembi #Eisai #negativedraftrecommendations #mildcognitiveimpairment #milddementia #Alzheimersdisease #NHSresources #NICEassessments #cognitiveimpairment
www.nice.org.uk/news/article...
www.nice.org.uk/news/article...
Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS
The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs
www.nice.org.uk
June 19, 2025 at 10:47 AM